CYDY News and Press, CytoDyn Inc From 01/29/20

The Big Game Is This Weekend; Looking or Some Penny Stocks To Watch? The biggest game in football will be hosted in Miami, FL this weekend but what does that mean for penny stocks ? Well, honestly, not much but when people are spending thousands on football tickets, they’re likely look...

Are Any of These Penny Stocks On Your Watch List This Week? Finding the best penny stocks to buy , let alone the best penny stocks to watch can be a difficult thing to do. It’s not a matter of finding the companies either. But rather researching the finer details of what could drive ...

VANCOUVER, Washington, Jan. 28, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today ann...

The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) Based on these strong results, CytoDyn has partnered with the Thai Red Cross AIDS Research Centre (TRCARC) to conduct clinica...

Acceptance underscores the scientific community’s recognition of leronlimab as a potential HIV prophylactic CytoDyn is currently partnered with the Thai Red Cross AIDS Research Centre (TRCARC) to develop and conduct clinical trials evaluating the potential of leronlimab to prev...

Immunomedics (IMMU) is in the final phase of its approval pathway with its antibody-drug conjugate ((ADC)) called sacituzumab govitecan, or IMMU-132. The company filed its amended BLA (Biologics License Application) on December 3rd 2019 . It was accepted and its PDUFA target action date is ...

Can The Latest Penny Stock News Spark More Momentum For These Companies? If there’s something that can become a quick catalyst for big moves for penny stocks , it’s news. Corporate updates tend to impact these low priced shares especially if the update is significant. We’...

VANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, anno...

VANCOUVER, Washington, Jan. 21, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

VANCOUVER, Washington, Jan. 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...